This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Bioconjugates
July 10-11, 2023
Digital Conference8:00AM EDT // 1:00PM BST //2:00PM CEST
Menu
Key Sessions
Mike Flanagan
Antibody Oligonucleotide Conjugates: Bridging Research and Clinical Applications
Avidity Biosciences, Inc., USA
Steven Dowdy
Endosomal escape of RNA Therapeutics and its Impact on the Efficacy of Next-generation Oligo Bioconjugates
UCSD School of Medicine, USA
keyboard_arrow_right

Bioconjugates - EST/EDT (Eastern Daylight, GMT-4)

keyboard_arrow_leftSearch & Filter
search

Bioconjugates - EST/EDT (Eastern Daylight, GMT-4)

search
Showing 1 of 1 Streams
8:00am - 8:05am
Welcoming Remarks
  • Lottie Leinfellner - Senior Digital Product Producer, Informa Connect, UK
8:05am - 8:35am
Expanding the Therapeutic Potential for ADCs: Looking at all Aspects of Drug Design
  • Bob Lutz - Chief Scientific Officer, Iksuda Therapeutics, USA
8:35am - 9:05am
Computational Assisted Drug Design for Modelling Conjugations Sites
  • Nidhin Thomas - Scientist I, Computational Drug Design, Novo Nordisk, USA
9:05am - 9:35am
Coffee Break & Networking Opportunities on the ConnectMe Platform
9:35am - 10:05am
Engineered RNA and Protein-Chemistry Platform Technology for Site-Selective and Specific Bioconjugations
  • Colby Souders - Chief Scientific Officer, Brick Bio, USA
10:05am - 10:35am
Linker Matters: Highly Stable and Efficient ADCs Made with Native Antibodies and Peptide Linkers
  • Philipp Probst - Associate Director ADC Research, Araris Biotech AG, Switzerland
10:35am - 11:05am
Legumain-cleavable ADCs with Kinesin Spindle Protein Inhibitor Payloads: Tailored Design for Solid Tumors and Heme Malignancies
  • Hans-Georg Lerchen - Managing Director and Chief Scientific Officer, Vincerx Pharma GmbH, Germany
11:05am - 11:35am
Coffee Break & Networking Opportunities on the ConnectMe Platform
11:35am - 12:05pm
Oligonucleotide Conjugates for Targeted Delivery to the Lung
  • Anna Rydzik - Associate Principal Scientist, AstraZeneca, Sweden
12:05pm - 12:35pm
Antibody Oligonucleotide Conjugates: Bridging Research and Clinical Applications
  • Mike Flanagan - Chief Scientific Officer/Chief Technical Officer, Avidity Biosciences, Inc., USA
12:35pm - 1:05pm
Introduction to the FORCE(tm) Platform for Targeted Delivery of Oligonucleotide Therapeutics
  • Nicholas Yoder - Senior Director, Platform Development, Dyne Therapeutics, USA
1:05pm - 1:35pm
Endosomal escape of RNA Therapeutics and its Impact on the Efficacy of Next-generation Oligo Bioconjugates
  • Steven Dowdy - Professor, UCSD School of Medicine, USA
1:35pm - 2:05pm
Efficient On-Target Delivery of Bioconjugates: In Vitro and In Vivo Performance of Sapreme’s Endosomal Escape Enhancers for Various Bioconjugates, Tissues and Targets
  • Miriam Bujny - Chief Development Officer, Sapreme Technologies, The Netherlands
NextBioconjugates
Filter
Topics
Choose Day